keyword
MENU ▼
Read by QxMD icon Read
search

placental angiogenic factors

keyword
https://www.readbyqxmd.com/read/29229743/meta-analysis-and-systematic-review-to-assess-the-role-of-soluble-fms-like-tyrosine-kinase-1-and-placenta-growth-factor-ratio-in-prediction-of-preeclampsia-the-sappphire-study
#1
Swati Agrawal, Ana Sofia Cerdeira, Christopher Redman, Manu Vatish
Preeclampsia is a major cause of morbidity and mortality worldwide. Numerous candidate biomarkers have been proposed for diagnosis and prediction of preeclampsia. Measurement of maternal circulating angiogenesis biomarker as the ratio of sFlt-1 (soluble FMS-like tyrosine kinase-1; an antiangiogenic factor)/PlGF (placental growth factor; an angiogenic factor) reflects the antiangiogenic balance that characterizes incipient or overt preeclampsia. The ratio increases before the onset of the disease and thus may help in predicting preeclampsia...
December 11, 2017: Hypertension
https://www.readbyqxmd.com/read/29229321/the-role-of-aspirin-heparin-and-other-interventions-in-the-prevention-and-treatment-of-fetal-growth-restriction
#2
REVIEW
Katie M Groom, Anna L David
Fetal growth restriction and related placental pathologies such as preeclampsia, stillbirth, and placental abruption are believed to arise in early pregnancy when inadequate remodeling of the maternal spiral arteries leads to persistent high-resistance and low-flow uteroplacental circulation. The consequent placental ischaemia, reperfusion injury, and oxidative stress are associated with an imbalance in angiogenic/antiangiogenic factors. Many interventions have centered on the prevention and/or treatment of preeclampsia with results pertaining to fetal growth restriction and small-for-gestational-age pregnancy often included as secondary outcomes because of the common pathophysiology...
December 8, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29222938/role-of-angiogenic-factors-in-the-pathogenesis-and-management-of-pre-eclampsia
#3
REVIEW
Nnabuike C Ngene, Jagidesa Moodley
The cause of pre-eclampsia is unknown. Different postulates have been developed to explain its pathogenesis. The two-stage theory and angiogenic imbalance are two notable postulates of the disease. Together, they propose that there is a lack of cytotrophoblastic invasion of the uterine spiral arteries in pre-eclampsia. The lumen of these arteries remains narrow instead of converting to the wide channels seen in normal pregnancy, and result in poor placental perfusion. Coupled with maternal susceptibility, this process leads to the release of mediators, including an excess of anti-angiogenic factors that result in the clinical manifestations of the disease...
December 9, 2017: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/29215518/angiogenic-factor-profiles-in-pregnant-women-with-a-history-of-early-onset-severe-preeclampsia-receiving-low-molecular-weight-heparin-prophylaxis
#4
Edouard Lecarpentier, Jean Christophe Gris, Eva Cochery-Nouvellon, Erick Mercier, Cyril Touboul, Ravi Thadhani, S Ananth Karumanchi, Bassam Haddad
OBJECTIVE: To evaluate whether daily low-molecular-weight (LMW) heparin prophylaxis during pregnancy alters profile of circulating angiogenic factors that have been linked with the pathogenesis of preeclampsia and fetal growth restriction. METHODS: This is a planned ancillary study of the Heparin-Preeclampsia trial, a randomized trial in pregnant women with a history of severe early-onset preeclampsia (less than 34 weeks of gestation). In the parent study, all women were treated with aspirin and then randomized to receive LMW heparin or aspirin alone...
December 4, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29208243/resveratrol-mitigates-trophoblast-and-endothelial-dysfunction-partly-via-activation-of-nuclear-factor-erythroid-2-related-factor-2
#5
Seshini Gurusinghe, Annie G Cox, Rahana Rahman, Siow T Chan, Ruth Muljadi, Harmeet Singh, Bryan Leaw, Joanne C Mockler, Sarah A Marshall, Padma Murthi, Rebecca Lim, Euan M Wallace
INTRODUCTION: Maternal endothelial dysfunction underlying preeclampsia arises from excessive placental release of anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt1), soluble endoglin (sEng) and activin A. Resveratrol, an activator of the nuclear factor erythroid 2-related factor-2 (Nrf2) transcription factor, mediates the gene expression of antioxidant and vasoprotective factors that may counter the endothelial damage imposed by these anti-angiogenic factors. The objective of this study was to assess whether resveratrol could reduce placental oxidative stress and production of anti-angiogenic factors in vitro and/or improve in vitro markers of endothelial dysfunction via Nrf2 activation...
December 2017: Placenta
https://www.readbyqxmd.com/read/29208172/investigation-of-role-of-vascular-endothelial-growth-factor-annexin-a5-and-apelin-by-immunohistochemistry-method-in-placenta-of-preeclampsia-patients
#6
Nese Colcimen, Gülay Bulut, Ozlem Ergul Erkec, Murat Cetin Ragbetli
Preeclampsia is a disease characterized by hypertension and proteinuria occurred after 20 weeks of gestation. Preeclampsia is a major cause of maternal and fetal morbidity and mortality.  The pathophysiological mechanism of preeclampsia is not known exactly yet. Preeclampsia endothelial cell dysfunction, associated with inadequate trophoblastic invasion is characterized by abnormal placentation. Vascular endothelial growth factor (VEGF) according to is an angiogenic cytokine, Annexin A5 is among endogenous peptides are both expressed from placental trophoblasts and Apelin is a multifunctional peptide and expressed by placental trophoblasts and endothelial cells...
November 30, 2017: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/29205570/brain-angiogenic-gene-expression-in-congenital-heart-disease
#7
Olga Sánchez, Aina Ruiz-Romero, Carmen Domínguez, Queralt Ferrer, Irene Ribera, Víctor Rodríguez-Sureda, Jaume Alijotas, Sílvia Arévalo, Elena Carreras, Lluís Cabero, Elisa Llurba
OBJECTIVES: To analyze potential differences in the expression of antiangiogenic and angiogenic factors and of genes associated with chronic hypoxia in cerebral tissue from euploid fetuses with congenital heart disease (CHD) and control fetuses. METHODS: Cerebral tissue was obtained from 15 fetuses with CHD and 12 control fetuses undergoing termination of pregnancy. Expression profiles of the antiangiogenic soluble fms-like tyrosine kinase-1 (sFlt-1), the angiogenic vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF), and genes associated with chronic hypoxia were determined by real-time PCR in tissue from the frontal cortex and from basal ganglia-hypothalamus...
December 5, 2017: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29196992/assessing-the-circulating-placental-specific-anti-angiogenic-protein-sflt-1-e15a-in-preeclampsia
#8
Kirsten Palmer
Preeclampsia is a common obstetric complication globally responsible for a significant burden of maternal and perinatal morbidity and mortality. The anti-angiogenic protein, sFLT-1, plays a central role in its pathophysiology. sFLT-1 is released from a range of tissues into the circulation, where it antagonizes the activity of vascular endothelial growth factor and placental growth factor leading to endothelial dysfunction. The resulting widespread endothelial dysfunction produces the clinical features of preeclampsia including hypertension and proteinuria...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29196991/biomarker-immunoassays-in-the-diagnosis-of-preeclampsia-calculating-the-sflt1-plgf-ratio-using-the-cobas%C3%A2-e-411-analyser
#9
Carin Black, Fabricio da Silva Costa
Preeclampsia is a relatively common pregnancy-related condition associated with serious maternal and fetal morbidity and mortality. It is now well established that anti-angiogenic sFlt1 is upregulated in preeclampsia and binds PlGF and VEGF, causing an imbalance in angiogenic factors with subsequent endothelial injury and dysfunction. Measurement of placental growth factor (PlGF) and the sFlt1/PlGF ratio have both been validated in other countries for screening and diagnosis of preeclampsia and the differentiation of preeclampsia from other hypertensive disorders of pregnancy...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29174227/angiogenic-and-antiangiogenic-factors-in-preeclampsia
#10
REVIEW
Fernanda Rodrigues Helmo, Angela Maria Moed Lopes, Anna Cecília Dias Maciel Carneiro, Carolina Guissoni Campos, Polyana Barbosa Silva, Maria Luíza Gonçalves Dos Reis Monteiro, Laura Penna Rocha, Marlene Antônia Dos Reis, Renata Margarida Etchebehere, Juliana Reis Machado, Rosana Rosa Miranda Corrêa
BACKGROUND: Pre-eclampsia is a multifactorial hypertensive disorder that is triggered by placental insufficiency and that accounts for up to 15% of maternal deaths. In normal pregnancies, this process depends on the balance between the expression of angiogenic factors and antiangiogenic factors, which are responsible for remodeling the spiral arteries, as well as for neoangiogenesis and fetal development. PURPOSE: The aim of this review is to discuss the main scientific findings regarding the role of angiogenic and antiangiogenic factors in the etiopathogenesis of preeclampsia...
October 31, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29168351/complement-5a-mediated-trophoblasts-dysfunction-is-involved-in-the-development-of-pre-eclampsia
#11
Yu Ma, Ling-Ran Kong, Qian Ge, Yuan-Yuan Lu, Mo-Na Hong, Yu Zhang, Cheng-Chao Ruan, Ping-Jin Gao
Pre-eclampsia (PE) is a life-threatening multisystem disorder leading to maternal and neonatal mortality and morbidity. Emerging evidence showed that activation of the complement system is implicated in the pathological processes of PE. However, little is known about the detailed cellular and molecular mechanism of complement activation in the development of PE. In this study, we reported that complement 5a (C5a) plays a pivotal role in aberrant placentation, which is essential for the onset of PE. We detected an elevated C5a deposition in macrophages and C5a receptor (C5aR) expression in trophoblasts of pre-eclamptic placentas...
November 23, 2017: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29135051/low-molecular-weight-heparin-and-aspirin-exacerbate-human-endometrial-endothelial-cell-responses-to-antiphospholipid-antibodies
#12
Zola Chihombori Quao, Mancy Tong, Elena Bryce, Seth Guller, Lawrence W Chamley, Vikki M Abrahams
PROBLEM: Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications despite treatment with low molecular weight heparin (LMWH) or aspirin (ASA). aPL recognizing beta2 glycoprotein I can target the uterine endothelium, however, little is known about its response to aPL. This study characterized the effect of aPL on human endometrial endothelial cells (HEECs), and the influence of LMWH and ASA. METHOD OF STUDY: HEECs were exposed to aPL or control IgG, with or without low-dose LMWH and ASA, alone or in combination...
November 14, 2017: American Journal of Reproductive Immunology: AJRI
https://www.readbyqxmd.com/read/29115294/placental-growth-factor-and-pre-eclampsia
#13
REVIEW
K Chau, A Hennessy, A Makris
Placental growth factor (PlGF) is an increasingly important molecule in the prediction, diagnosis and treatment of pre-eclampsia. It has pro-angiogenic effects on the feto-placental circulation and supports trophoblast growth. Mechanisms by which PlGF expression is regulated continue to be investigated. Low circulating PlGF precedes the manifestation of clinical disease in pre-eclamptic pregnancies and intrauterine growth restriction. This suggests that low PlGF is a marker of abnormal placentation, but it remains uncertain whether this is a cause or consequence...
December 2017: Journal of Human Hypertension
https://www.readbyqxmd.com/read/29111087/angiogenic-factor-screening-in-women-with-mild-preeclampsia-new-and-significant-proteins-in-plasma
#14
Karol Charkiewicz, Elwira Jasinska, Joanna Goscik, Ewa Koc-Zorawska, Marcin Zorawski, Pawel Kuc, Grzegorz Raba, Tomasz Kluz, Jaroslaw Kalinka, Agata Sakowicz, Piotr Laudanski
INTRODUCTION: The aim of this study was to analyse a panel of 60 angiogenic factors (pro-angiogenic and antiangiogenic) in the plasma of women with mild preeclampsia. MATERIALS AND METHODS: We recruited 21 women between 25 and 40 weeks gestation with diagnosed mild preeclampsia into the study group and 27 healthy women with uncomplicated pregnancies of corresponding gestational age to that of the study to the control group. We used a quantitative protein macroarray method that allowed for analysis of 60 angiogenic proteins per sample simultaneously...
October 27, 2017: Cytokine
https://www.readbyqxmd.com/read/29095861/identification-of-proteins-associated-with-clinical-and-pathological-features-of-proliferative-diabetic-retinopathy-in-vitreous-and-fibrovascular-membranes
#15
Ingeborg Klaassen, Ewout W de Vries, Ilse M C Vogels, Antoine H C van Kampen, Machteld I Bosscha, David H W Steel, Cornelis J F Van Noorden, Sarit Y Lesnik-Oberstein, Reinier O Schlingemann
PURPOSE: To identify the protein profiles in vitreous associated with retinal fibrosis, angiogenesis, and neurite formation in epiretinal fibrovascular membranes (FVMs) in patients with proliferative diabetic retinopathy (PDR). METHODS: Vitreous samples of 5 non-diabetic control patients with vitreous debris and 7 patients with PDR membranes were screened for 507 preselected proteins using the semi-quantitative RayBio® L-series 507 antibody array. From this array, 60 proteins were selected for a custom quantitative antibody array (Raybiotech, Human Quantibody® array), analyzing 7 control patients, 8 PDR patients with FVMs, and 5 PDR patients without FVMs...
2017: PloS One
https://www.readbyqxmd.com/read/29054861/regulation-of-human-feto-placental-endothelial-barrier-integrity-by-vascular-endothelial-growth-factors-competitive-interplay-between-vegf-a165a-vegf-a165b-pigf-and-ve-cadherin
#16
Vincent Pang, David O Bates, Lopa Leach
The human placenta nourishes and protects the developing fetus whilst influencing maternal physiology for fetal advantage. It expresses several members of the VEGF family including the pro-angiogenic/pro-permeability VEGF-A165a isoform, the anti-angiogenic VEGF-A165b, placental growth factor (PIGF) and their receptors, VEGFR1 and VEGFR2. Alterations in the ratio of these factors during gestation and in complicated pregnancies have been reported; however the impact of this on feto-placental endothelial barrier integrity is unknown...
October 20, 2017: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29037482/a-low-angiogenic-index-1-placental-growth-factor-soluble-vascular-endothelial-growth-factor-receptor-1-ratio-at-24-28-weeks-of-gestation-is-a-biomarker-to-identify-the-patient-at-risk-for-subsequent-fetal-death
#17
Tinnakorn Chaiworapongsa, Roberto Romero, Offer Erez, Adi L Tarca, Agustin Conde-Agudelo, Piya Chaemsaithong, Chong Jai Kim, Yeon Mee Kim, Jung-Sun Kim, Bo Hyun Yoon, Sonia S Hassan, Lami Yeo, Steven J Korzeniewski
OBJECTIVE: We sought to determine if maternal plasma concentrations of angiogenic and antiangiogenic factors measured at 24-28 weeks of gestation can predict subsequent fetal death. STUDY DESIGN: A case-cohort study was designed to include 1000 randomly selected subjects and all remaining fetal deaths (cases) from a cohort of 4006 women with a singleton pregnancy, enrolled at 6-22 weeks of gestation, in a pregnancy biomarker cohort study. The placentas of all fetal deaths were histologically examined by pathologists who used a standardized protocol and were blinded to patient outcomes...
October 13, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29031892/altered-angiogenesis-as-a-common-mechanism-underlying-preterm-birth-small-for-gestational-age-and-stillbirth-in-women-living-with-hiv
#18
Andrea L Conroy, Chloe R McDonald, Joel L Gamble, Peter Olwoch, Paul Natureeba, Deborah Cohan, Moses R Kamya, Diane V Havlir, Grant Dorsey, Kevin C Kain
BACKGROUND: Angiogenic processes in the placenta are critical regulators of fetal growth and impact birth outcomes, but there are limited data documenting these processes in HIV-infected women or women from low-resource settings. OBJECTIVE: We sought to determine whether angiogenic factors are associated with adverse birth outcomes in HIV-infected pregnant women started on antiretroviral therapy. STUDY DESIGN: This is a secondary analysis of samples collected as part of a clinical trial randomizing pregnant women infected with HIV to lopinavir/ritonavir-based (n = 166) or efavirenz-based (n = 160) antiretroviral therapy in Tororo, Uganda...
October 12, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29023811/placental-growth-factor-inhibition-targets-pulmonary-angiogenesis-and-represents-a-novel-therapy-for-hepatopulmonary-syndrome-in-mice
#19
Sarah Raevens, Anja Geerts, Annelies Paridaens, Sander Lefere, Xavier Verhelst, Anne Hoorens, Jo Van Dorpe, Tania Maes, Ken R Bracke, Christophe Casteleyn, Bart Jonckx, Thomas Horvatits, Valentin Fuhrmann, Hans Van Vlierberghe, Christophe Van Steenkiste, Lindsey Devisscher, Isabelle Colle
Hepatopulmonary syndrome (HPS) is a severe complication of cirrhosis with increased risk of mortality. Pulmonary microvascular alterations are key features of HPS, but underlying mechanisms are incompletely understood, and studies on HPS are limited to rats. Placental growth factor (PlGF), a pro-angiogenic molecule that is selectively involved in pathological angiogenesis, may play an important role in HPS development, however, its role has never been investigated. In this study, we validated an HPS model by common bile duct ligation (CBDL) in mice, investigated the kinetic changes in pulmonary angiogenesis and inflammation during HPS development, and provide evidence for a novel therapeutic strategy by targeting pathological angiogenesis...
October 10, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28986273/ite-suppresses-angiogenic-responses-in-human-artery-and-vein-endothelial-cells-differential-roles-of-ahr
#20
Yan Li, Kai Wang, Qing-Yun Zou, Yi-Zhou Jiang, Chi Zhou, Jing Zheng
Aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor is involved in regulation of many essential biological processes including vascular development and angiogenesis. 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) is an AhR ligand, which regulates immune responses and cancer cell growth. However, the roles of the ITE/AhR pathway in mediating placental angiogenesis remains elusive. Here, we determined if ITE affected placental angiogenic responses via AhR in human umbilical vein (HUVECs) and artery endothelial (HUAECs) cells in vitro...
October 3, 2017: Reproductive Toxicology
keyword
keyword
108506
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"